The 2012 Briganti nomogram not only predicts lymph node involvement but also disease progression in surgically treated intermediate-risk prostate cancer patients with PSA <10 ng/mL, ISUP grade group 3, and clinical stage up to cT2b.
Antonio Benito PorcaroAndrea PanunzioRossella OrlandoFrancesca MontanaroAlberto BaielliFrancesco ArtoniSebastian GallinaAlberto BianchiGiovanni MazzucatoEmanuele SerafinGiulia Marafioti PatuzzoAlessandro VecciaRiccardo RizzettoMatteo BrunelliFilippo MiglioriniRiccardo BertoloAlessandro TafuriMaria Angela CerrutoAlessandro AntonelliPublished in: International braz j urol : official journal of the Brazilian Society of Urology (2024)
In IR PCa patients with PSA <10ng/mL, ISUP grade group 3, and clinical stage up to cT2b, the 2012 Briganti nomogram independently predicts PCa progression. In this challenging subset of patients, this tool can identify prognostic subgroups, independently by upgrading issues.
Keyphrases
- prostate cancer
- lymph node
- radical prostatectomy
- newly diagnosed
- end stage renal disease
- computed tomography
- image quality
- ejection fraction
- contrast enhanced
- dual energy
- lymph node metastasis
- chronic kidney disease
- prognostic factors
- positron emission tomography
- radiation therapy
- magnetic resonance imaging
- early stage
- rectal cancer
- locally advanced